Unveiling unexpected adverse events and haemorrhagic safety: post-marketing safety surveillance of ramucirumab from the FAERS database

Key Points

• The aim is to evaluate the safety profile of ramucirumab using post-marketing data.
• Analyzed data from the FAERS database
• Identified adverse events associated with ramucirumab
• Examined signals related to haemorrhage
• Detected unexpected adverse events linked to ramucirumab
• Highlighted a new subgroup experiencing haemorrhage
• Called for further investigation of these safety signals